Clinical implications from a single-center study of colorectal adenocarcinoma in transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim S.M. | - |
dc.contributor.author | Jung M. | - |
dc.contributor.author | Shin S.J. | - |
dc.contributor.author | Baek S.J. | - |
dc.contributor.author | Hur H. | - |
dc.contributor.author | Min B.S. | - |
dc.contributor.author | Baik S.H. | - |
dc.contributor.author | Kim N.K. | - |
dc.contributor.author | Ahn J.-B. | - |
dc.date.available | 2020-11-02T19:43:46Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.issn | 1423-0232 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/9935 | - |
dc.description.abstract | Background: With the increasing burden of organ transplant recipients and improvements in allograft outcome, the incidence of neoplasms rising from these patients is an important issue. Objective: In this study, we investigated transplant recipients with colorectal cancer to determine its incidence, clinicopathological characteristics, and prognosis. Methods: The database of Severance Hospital was queried for all cases of colorectal adenocarcinoma among transplant recipients from August 2005 to January 2013. Results: A total of 29 patients were diagnosed with colorectal adenocarcinoma after transplantation, and the median age at diagnosis was 58.6 years. As for primary tumor stage, 17 (58.6%) patients had stage ≥3, and distant metastasis was found in 10 (34.4%) patients. The mean time from transplantation to tumor detection was 13.7 years. The median disease-free survival was 11.0 months and the median overall survival (OS) was 18.1 months. In multivariate analysis of prognostic factors for OS, surgical resection was a positive prognostic factor (HR 1.357, p = 0.010) and the presence of distant metastasis at diagnosis was a negative prognostic factor (HR 1.047, p = 0.006). Conclusion: The behavior of colorectal cancer in posttransplant patients is more aggressive and refractory to treatment. A separate guideline for the colorectal screening program for the posttransplant patients needs to be established. © 2014 S. Karger AG, Basel. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | S. Karger AG | - |
dc.title | Clinical implications from a single-center study of colorectal adenocarcinoma in transplant recipients | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.1159/000369254 | - |
dc.identifier.scopusid | 2-s2.0-84926406655 | - |
dc.identifier.wosid | 000351884700001 | - |
dc.identifier.bibliographicCitation | Oncology (Switzerland), v.88, no.4, pp 195 - 200 | - |
dc.citation.title | Oncology (Switzerland) | - |
dc.citation.volume | 88 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 195 | - |
dc.citation.endPage | 200 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | fluorouracil | - |
dc.subject.keywordPlus | oxaliplatin | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | bone metastasis | - |
dc.subject.keywordPlus | cancer incidence | - |
dc.subject.keywordPlus | cancer prognosis | - |
dc.subject.keywordPlus | cancer staging | - |
dc.subject.keywordPlus | cancer surgery | - |
dc.subject.keywordPlus | carcinomatosis | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | colorectal carcinoma | - |
dc.subject.keywordPlus | data base | - |
dc.subject.keywordPlus | disease free survival | - |
dc.subject.keywordPlus | distant metastasis | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | graft recipient | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | liver metastasis | - |
dc.subject.keywordPlus | lung metastasis | - |
dc.subject.keywordPlus | lymph node metastasis | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | metastasis resection | - |
dc.subject.keywordPlus | multivariate analysis | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | adenocarcinoma | - |
dc.subject.keywordPlus | Colorectal Neoplasms | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | graft recipient | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | mortality | - |
dc.subject.keywordPlus | organ transplantation | - |
dc.subject.keywordPlus | prognosis | - |
dc.subject.keywordPlus | survival rate | - |
dc.subject.keywordPlus | young adult | - |
dc.subject.keywordPlus | Adenocarcinoma | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Colorectal Neoplasms | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Follow-Up Studies | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Neoplasm Staging | - |
dc.subject.keywordPlus | Organ Transplantation | - |
dc.subject.keywordPlus | Prognosis | - |
dc.subject.keywordPlus | Survival Rate | - |
dc.subject.keywordPlus | Transplant Recipients | - |
dc.subject.keywordPlus | Young Adult | - |
dc.subject.keywordAuthor | Colorectal cancer | - |
dc.subject.keywordAuthor | Organ transplantation | - |
dc.subject.keywordAuthor | Survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.